Smoking Cessation, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Peter G. Shields, Laura J. Bierut, Douglas A. Arenberg, David S. Balis, Paul M. Cinciripini, James M. Davis, Donna Edmondson, Joy Feliciano, Brian Hitsman, Karen Suchanek Hudmon, Michael T. Jaklitsch, Frank T. Leone, Pamela M. Ling, Danielle E. McCarthy, Michael Ong, Elyse R. Park, Judith J. Prochaska, Argelia Sandoval, Christine E. Sheffer, Sharon Spencer, Jamie L. Studts, Tawee Tanvetyanon, Hilary A. Tindle, Elisa K. Tong, Matthew Triplette, James J. Urbanic, Gregory M.M. Videtic, David O. Warner, C. Will Whitlock, Beth McCullough, Susan Darlow
Abstract
Although the harmful effects of smoking after a cancer diagnosis have been clearly demonstrated, many patients continue to smoke cigarettes during treatment and beyond. The NCCN Guidelines for Smoking Cessation emphasize the importance of smoking cessation in all patients with cancer and seek to establish evidence-based recommendations tailored to the unique needs and concerns of patients with cancer. The recommendations contained herein describe interventions for cessation of all combustible tobacco products (eg, cigarettes, cigars, hookah), including smokeless tobacco products. However, recommendations are based on studies of cigarette smoking. The NCCN Smoking Cessation Panel recommends that treatment plans for all patients with cancer who smoke include the following 3 tenets that should be done concurrently: (1) evidence-based motivational strategies and behavior therapy (counseling), which can be brief; (2) evidence-based pharmacotherapy; and (3) close follow-up with retreatment as needed.